Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Matteo S. Carlino; Georgina V. Long; Richard F. Kefford; Helen Rizos

doi:10.1016/j.critrevonc.2015.08.021

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Matteo S. Carlino^*, Georgina V. Long, Richard F. Kefford, Helen Rizos

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

47 Citations (Scopus)

Abstract

BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.

Original language	English
Pages (from-to)	385-398
Number of pages	14
Journal	Critical Reviews in Oncology/Hematology
Volume	96
Issue number	3
DOIs	https://doi.org/10.1016/j.critrevonc.2015.08.021
Publication status	Published - 1 Dec 2015

Access to Document

10.1016/j.critrevonc.2015.08.021

Cite this

@article{99553bb4fb82450fa6e45089faaf6038,

title = "Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma",

abstract = "BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor na{\"i}ve and resistant BRAF mutant melanoma.",

author = "Carlino, {Matteo S.} and Long, {Georgina V.} and Kefford, {Richard F.} and Helen Rizos",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.critrevonc.2015.08.021",

language = "English",

volume = "96",

pages = "385--398",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

AU - Carlino, Matteo S.

AU - Long, Georgina V.

AU - Kefford, Richard F.

AU - Rizos, Helen

PY - 2015/12/1

Y1 - 2015/12/1

N2 - BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.

AB - BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84983103421&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.08.021

DO - 10.1016/j.critrevonc.2015.08.021

M3 - Review article

C2 - 26358420

AN - SCOPUS:84983103421

SN - 1040-8428

VL - 96

SP - 385

EP - 398

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

IS - 3

ER -

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this